Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive Individuals
Déc. 31, 2024
31 Déc. 2024
at 5:00 PM EST
Edwin DeJesus, MD, William J. Towner, Jr, MD, Joseph C Gathe, MD, R. Brandon Cash, PharmD, and Kaitlin Anstett, PhD